Glycopyrronium Bromide Martindale Pharmaceuticals

Glycopyrronium Bromide Martindale Pharmaceuticals is a prescription injectable medication that contains the anticholinergic agent glycopyrronium bromide. It is supplied by Martindale Pharmaceuticals for use under medical supervision; the specific strength and dosage form are determined by the prescribing clinician based on the intended therapeutic application.

Glycopyrronium bromide is employed in several clinical settings where reduction of secretions or bronchodilation is desired.

- Preoperative reduction of salivary, bronchial, and gastric secretions to facilitate anesthesia. - Management of bronchospasm associated with chronic obstructive pulmonary disease (COPD). - Adjunct therapy for asthma when other bronchodilators are insufficient. - Treatment of excessive airway secretions in patients requiring mechanical ventilation. - Use in diagnostic procedures where airway secretions may interfere with results.

Side effects of glycopyrronium bromide reflect its anticholinergic activity on muscarinic receptors.

Common: - Dry mouth (xerostomia). - Throat irritation. - Nasal dryness. - Mild headache. - Transient increase in heart rate. - Flushing of the skin.

Serious: - Severe bronchospasm. - Cardiac arrhythmias. - Acute urinary retention. - Vision disturbances such as blurred vision. - Allergic reactions including rash, itching, or anaphylaxis.

When prescribing glycopyrronium bromide, clinicians should consider several safety factors.

- Assess patient history for glaucoma, urinary retention, or gastrointestinal obstruction. - Use caution in patients with cardiovascular disease or tachyarrhythmias. - Monitor for signs of excessive anticholinergic burden, especially in the elderly. - Adjust dose or avoid use in patients with known hypersensitivity to glycopyrronium or related compounds. - Evaluate renal and hepatic function, as impairment may affect drug clearance. - Ensure appropriate timing relative to anesthesia to avoid prolonged secretory suppression.

Glycopyrronium bromide may interact with other medications that influence cholinergic pathways or cardiac function.

Avoid: - Other anticholinergic agents (e.g., atropine, scopolamine) that may amplify anticholinergic side effects. - Drugs that prolong the QT interval when combined with significant tachycardia.

Use with caution: - Beta‑agonist bronchodilators, as combined effects on heart rate may occur. - Medications that increase secretions, such as cholinesterase inhibitors. - Drugs metabolized by hepatic enzymes that could be inhibited or induced, potentially altering glycopyrronium levels. - Anesthetic agents that may synergize with anticholinergic effects on airway secretions.